Olsalazine

Olsalazine

Systematic (IUPAC) name
5-[(2Z)-2-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)hydrazino]-2-hydroxybenzoic acid
Clinical data
Trade names	Dipentum
AHFS/Drugs.com	monograph
MedlinePlus	a601088
Pregnancy cat.	C (US)
Legal status	℞-only (US)
Pharmacokinetic data
Protein binding	99%
Half-life	0.9 hours
Identifiers
CAS number	15722-48-2 Y
ATC code	A07EC03
PubChem	CID 6003770
DrugBank	DB01250
ChemSpider	10642377 Y
UNII	ULS5I8J03O Y
KEGG	D00727 N
ChEMBL	CHEMBL571540 N
Chemical data
Formula	C14H10N2O6
Mol. mass	302.239g/mol
SMILES O=C(O)c1cc(ccc1O)/N=N/c2cc(C(O)=O)c(O)cc2
InChI InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+ Y Key:QQBDLJCYGRGAKP-FOCLMDBBSA-N Y
N (what is this?)  (verify)

Olsalazine is an anti-inflammatory drug used in the treatment of inflammatory bowel disease such as ulcerative colitis. It is sold under the name Dipentum.

The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt.

Like balsalazide, olsalazine is believed to deliver mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis.

History

Olsalazine gained Food and Drug Administration (FDA) approval in 1990.

Supply

The drug is supplied by UCB Pharma.

Other indications

The Australian biotech company Giaconda has developed a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine.

External links

• Olsalazine official site
• Medicine Net